<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eton Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc</link>
<description>Latest news and press releases for Eton Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eton-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683564de78dffbe2df0efd7d.webp</url>
<title>Eton Pharmaceuticals Inc</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc</link>
</image>
<item>
<title>Eton Pharmaceuticals Announces CFO Succession Plan</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-cfo-succession-plan</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-cfo-succession-plan</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton</description>
</item>
<item>
<title>Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP</description>
</item>
<item>
<title>Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-march-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-march-19-2026</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Web</description>
</item>
<item>
<title>Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-expands-rare-disease-portfolio-through-acquisition-of-us-commercialization-rights-to-hemangeolr-propranolol-hydrochloride-oral-solution</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-expands-rare-disease-portfolio-through-acquisition-of-us-commercialization-rights-to-hemangeolr-propranolol-hydrochloride-oral-solution</guid>
<pubDate>Mon, 02 Mar 2026 12:27:00 GMT</pubDate>
<description>HEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access. DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rar</description>
</item>
<item>
<title>Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-us-fda-approval-for-desmodatm-desmopressin-acetate-oral-solution</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-us-fda-approval-for-desmodatm-desmopressin-acetate-oral-solution</guid>
<pubDate>Wed, 25 Feb 2026 18:47:00 GMT</pubDate>
<description>DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044 DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Na</description>
</item>
<item>
<title>Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-to-participate-at-leerink-partners-global-healthcare-conference-on-wednesday-march-11th</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-to-participate-at-leerink-partners-global-healthcare-conference-on-wednesday-march-11th</guid>
<pubDate>Fri, 20 Feb 2026 11:50:00 GMT</pubDate>
<description>DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. To schedule a 1x1 meeting with the Company, please contact your Leeri</description>
</item>
<item>
<title>Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-licensing-rare-115000098</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-licensing-rare-115000098</guid>
<pubDate>Mon, 02 Feb 2026 11:50:00 GMT</pubDate>
<description>Product is currently under review with the FDAPotential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a</description>
</item>
<item>
<title>Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-present-piper-sandler-37th-annual-healthcare-conference-december</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-present-piper-sandler-37th-annual-healthcare-conference-december</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-16th-annual-craig-hallum-alpha-select-conference</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-16th-annual-craig-hallum-alpha-select-conference</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and</description>
</item>
<item>
<title>Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-third-quarter-2025-financial-results-thursday-november-6</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-third-quarter-2025-financial-results-thursday-november-6</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-2025-wells-fargo-healthcare-conference-2025-08-20</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-2025-wells-fargo-healthcare-conference-2025-08-20</guid>
<pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-08-07</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-08-07</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic</description>
</item>
<item>
<title>Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-second-quarter-2025-financial-results-thursday-august-7</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-second-quarter-2025-financial-results-thursday-august-7</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-fda-acceptance-new-drug-application-et-600</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-fda-acceptance-new-drug-application-et-600</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-addition-russell-2000r-and-russell-3000r-indexes-2025</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-addition-russell-2000r-and-russell-3000r-indexes-2025</guid>
<pubDate>Fri, 27 Jun 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-us-fda-approval-khindivitm-hydrocortisone-oral</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-announces-us-fda-approval-khindivitm-hydrocortisone-oral</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales</description>
</item>
<item>
<title>Eton Pharmaceuticals to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-upcoming-investor-conferences-2025-05-14</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-participate-upcoming-investor-conferences-2025-05-14</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
<item>
<title>Eton Pharmaceuticals Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-first-quarter-2025-financial-results-2025-05-13</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-reports-first-quarter-2025-financial-results-2025-05-13</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential</description>
</item>
<item>
<title>Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025</title>
<link>https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-first-quarter-2025-financial-results-tuesday-may-13-2025</link>
<guid isPermaLink="true">https://6ix.com/company/eton-pharmaceuticals-inc/news/eton-pharmaceuticals-report-first-quarter-2025-financial-results-tuesday-may-13-2025</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company</description>
</item>
</channel>
</rss>